Herantis Pharma Plc, Company release, 5 December 2022 at 09:00 EET
Herantis Pharma will be traded solely on Nasdaq First North Growth Market Finland under the trading code: HRTIS
Herantis Pharma Plc (“Herantis”) is developing disease modifying therapies for Parkinson’s disease. As announced on December 1, 2022, Herantis applied for delisting of its shares from Nasdaq First North Growth Market Sweden (“Nasdaq FN GM Sweden”).
Nasdaq Stockholm AB approved the application December 2, 2022 and decided to delist the shares of Herantis (trading code HRNTS, ISIN code FI4000087861) from Nasdaq FN GM Sweden.
The last day of trading in the shares of Herantis on Nasdaq First North Growth Market Sweden shall be January 31, 2023.
The Company wants to remind Herantis’ shareholders holding their shares through Euroclear Sweden AB that even while the listing of Herantis’ shares on Nasdaq FN GM Sweden will be discontinued, such shareholders can continue trading in Herantis’ shares on Nasdaq First North Growth Market Finland by first arranging for the cross-border settlement of their shares into the book-entry system maintained by Euroclear Finland Oy.
Aqurat Fondkommission AB acts as Herantis’ Issuing Agent and will coordinate the conversion process:
- Instructive letter will be distributed to directly registered shareholders and to all custodians
- The instructive letter explains the conversion process and actions to be taken
- Cross-border settlement will be done weekly
Shareholders should contact their respective custodian or Herantis Issuing Agent Aqurat Fondkommission AB (email@example.com) for more information.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information, please visit www.herantis.com.